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ABSTRACT: Symptoms of atopic asthma often disappear around puberty. The authors
recently demonstrated that this clinical remission is accompanied with ongoing airways
inflammation in most subjects. The discrepancy between lack of symptoms and persis-
tent airway inflammation suggests that perception of the symptoms is unclear. In the
present study, young adults in clinical remission of atopic asthma assigned themselves a
modified Borg score during methacholine and adenosine-59-monophosphate induced
bronchoconstriction. Borg scores of subjects in clinical remission were compared with
those of symptomatic asthmatic subjects. A marked variation in the Borg scores at a
20% fall in the forced expiratory volume in one second was found. Significant differ-
ences in Borg scores between remission patients and asthmatics could not be detected.
It was concluded that perception of dyspnoea, induced with methacholine and
adenosine challenge, is similar in young adults in clinical remission of atopic asthma
compared to that of patients with symptomatic asthma. Hence, an unclear perception
seems to be an unlikely explanation for the discrepancy between lack of symptoms and
ongoing inflammation. Other factors, including both physical and psychological ones,
may play a role in the apparent absence of symptoms, thereby potentially leading to
undertreatment.
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In asthma, symptoms often decrease or even seem
to disappear around puberty. Unfortunately, clinical
remission is followed by a relapse later in life in a
considerable proportion of subjects [1, 2]. The authors
recently found ongoing airways inflammation during
clinical remission of atopic asthma [3, 4]. Persistent
airways inflammation during clinical remission would
possibly explain the high relapse rate. The relationship
between dyspnoea perception and other indices of
asthmatic severity, such as the degree of broncho-
constriction, is poor [5, 6]. Conversely, impaired
dyspnoea perception is especially believed to play
a role in severe asthma [7–9]. Poor perception of
airflow obstruction may lead to undertreatment of
asthma [10]. Especially in view of the high relapse
rate of asthma later in life, diminished perception of
dyspnoea in subjects in clinical remission of asthma
is of great clinical relevance. Therefore, the hypothesis
of the present study was that subjects in clinical
remission of atopic asthma have blunted perception of
dyspnoea. Dyspnoea scores, including visual analogue
scale (VAS) scores and (modified) Borg scores, can
be assessed during spontaneous asthma or during
induced bronchoconstriction [11]. The aim of the
present study was to compare dyspnoea scores during
induced bronchoconstriction between young adults
in clinical remission of asthma and currently sympto-
matic asthmatic subjects. Since the mechanism of
bronchoconstriction differs between direct stimuli
(methacholine (MCh)) and indirect stimuli (adenosine
monophosphate (AMP)), and may give rise to a
different perception, MCh as well as AMP challenges
were used in both groups.
Subjects, materials and methods
Subjects
Young adults with atopic asthma, aged 18–25 yrs,
were selected from the Sophia Children9s Hospital
(Rotterdam, the Netherlands) discharged patients
files. Clinical remission of atopic asthma was defined
as reported complete absence of cough, wheezing and
breathlessness at rest and on exertion in subjects not
taking any asthma medication for at least 12 months
prior to the study. Approximately 80% of subjects in
clinical remission showed elevated nitric oxide levels,
eosinophilic airway inflammation, and hyperrespon-
siveness to both MCh and AMP [3, 4]. All subjects
responding with a 20% fall in the forced expira-
tory volume in one second (FEV1) during induced
bronchoconstriction with MCh or AMP were con-
sidered eligible for the present study. Ten eligible
subjects in remission were included, and compared
with 10 patients with asthma who had persistent
symptoms, assessed with the short-form (SF)-36
health survey quality of life/symptom score form, at
Eur Respir J 2002; 19: 1047–1050
DOI: 10.1183/09031936.02.01712001
Printed in UK – all rights reserved
Copyright #ERS Journals Ltd 2002
European Respiratory Journal
ISSN 0903-1936
least once a month in the year preceding the study,
and used inhaled b2-agonists on demand in order to
relieve symptoms. Subjects with current asthma could
thus be defined as having "mild persistent asthma"
according to global initiative for asthma (GINA)
guidelines. All subjects had a history of wheezing
and chest tightness and were previously diagnosed
as having asthma according to American Thoracic
Society (ATS) criteria [12]. All were atopic defined as
radio allergosorbent test (RAST) class 2 or higher for
at least one common airborne allergen. All subjects
were lifelong nonsmokers in a stable clinical condition
and did not take inhaled steroids, including nasal
steroids, or anti-allergic medication like cromoglycate
and antihistamines for at least 1 yr prior to the study.
Common exclusion criteria were an inability to
perform lung function tests reproducibly, and illnesses
that may have affected lung function. None of the
subjects in the study reported symptoms of respiratory
infection in the month prior to the study.
The study was approved by the Medical Ethics
Committee of the Erasmus University Medical
Centre, Rotterdam (the Netherlands).
Study design
A cross-sectional study with two visits on separate
days was performed. At the first visit, subjects gave
informed written consent and were asked about their
asthmatic symptoms, history and requirement of
rescue medication during the past year. Also, physical
examination was performed, followed by determina-
tion of MCh responsiveness. At the second visit,
scheduled at least 1 day after visit one, subjects
underwent an AMP challenge test. During the tests,
subjects were asked to score their degree of breath-
lessness after each given dose according to a modified
Borg scale. The sequence and intervals of the provoca-
tion tests were chosen in order to avoid any influence
of the AMP challenge on MCh responsiveness [13].
Methacholine and adenosine-59-monophosphate
challenge
Challenge tests were performed at the same time
of day (¡1 h) according to the dosimeter method
as described in detail earlier [3, 14]. Short-acting
b2-agonists were not allowed within 8 h prior to the
test. If a patient responded to saline or the lowest
concentration of either MCh or AMP, they were
assigned a provocative dose causing a 20% fall in the
FEV1 (PD20) value of half the starting dose. Inhala-
tion provocation tests were performed using doubling
concentrations of 0.15–78.4 mg?mL-1 MCh bromide
in phosphate-buffered saline or 0.08–160 mg?mL-1
AMP in normal saline (Sigma Chemical Co., St.
Louis, MO, USA). During MCh and AMP challenge,
before each FEV1 measurement, perception of dys-
pnoea was assessed on a modified Borg scale. A
perception score at a 20% fall in FEV1 (PS20) was
obtained by interpolation of the two last points on the
perception/fall in FEV1 curve [10].
Statistical analysis
Data are expressed as mean PS20¡SEM. Compar-
isons between groups were made by an unpaired
t-test. A two-tailed p-value ofv0.05 was considered
significant. Correlation was expressed as a partial
correlation coefficient.
Results
Twenty subjects could be assigned both a PS20
MCh value and a PS20 AMP value (10 subjects with
currently symptomatic atopic asthma and 10 subjects
in clinical remission of asthma). The subject charac-
teristics are summarized in table 1. The two groups
were comparable with respect to age, FEV1 and PD20
AMP. PD20 MCh in currently symptomatic asthmatic
subjects was significantly lower than in subjects in
clinical remission (p=0.034).
All subjects, including the ones in clinical remission,
experienced some degree of dyspnoea at reaching a
20% decrease in FEV1, even though there was a
marked within-group variation in PS20 (for instance
0.5–9 in the remission group with respect to MCh
provocation). Nevertheless, for both inhaled stimuli
no significant difference between currently asthmatic
subjects and subjects in clinical remission with respect
to PS20 could be detected (figs. 1 and 2).
Mean PS20 MCh was 2.7¡1.1 (range 1–4) and
3.2¡2.5 (range 0.5–9) for currently asthmatic subjects
and subjects in remission, respectively, and 3.3¡1.3
(range 1–5) versus 3.7¡1.9 (range 0.5–6) with respect
to AMP-induced bronchoconstriction. The authors
did not find a significant relationship between
bronchial responsiveness, expressed as PD20, and
respiratory distress at reaching a 20% decrease in
FEV1 for both inhaled stimuli (r=0.23 and p=0.34 for
MCh; r=0.06 and p=0.81 for AMP; figs. 3 and 4).
Discussion
In this study no significant difference in dyspnoea
perception between currently asthmatic subjects and
subjects in clinical remission of atopic asthma at 20%
fall in FEV1 with MCh and AMP-induced broncho-
constriction was found. MCh responsiveness differed
Table 1. –Subject characteristics
Asthmatic subjects Remission subjects
Subjects n 10 10
Age yrs 22.5¡0.5 (19–25) 20.6¡0.6 (19–24)
Sex M:F 7:3 10:0
FEV1 L?min-1 90¡3 (80–106) 91¡4 (63–107)
PD20 MCh mmol 0.4¡0.3 (0.1–2.8) 2.3¡1.1 (0.1–9.9)
PD20 AMP mmol 5.3¡2.3 (0.6–27.3) 9.8¡2.6 (1.0–22.2)
Age and forced expiratory volume in one second (FEV1) are
presented as mean¡SEM (range) and the provocative dose
causing a 20% fall in the FEV1 (PD20) as median¡SEM
(range). MCh: methacholine; AMP: adenosine monopho-
sphate; M: male; F: female.
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significantly between subjects in remission and cur-
rently symptomatic asthmatics, whereas AMP respon-
siveness did not. All subjects experienced some degree
of dyspnoea at reaching a 20% fall in FEV1. Dyspnoea
scores varied from "very slight dyspnoea" to "almost
extreme dyspnoea". A significant correlation between
dyspnoea perception and degree of bronchial hyper-
responsiveness could not be detected.
The finding that MCh-, but not AMP responsive-
ness differs significantly between subjects in clinical
remission and currently asthmatic subjects, can be
explained by differences in the mechanism of action.
Where MCh responsiveness may be influenced by
structural changes in the airways and active airway
inflammation, AMP is believed to reflect only active
airway inflammation, including an increased number
of mast cells. Thus, since currently asthmatic subjects
may suffer from both more pronounced structural
changes and more active inflammation, as compared
with subjects in remission, MCh responsiveness may
separate the groups better than AMP responsiveness.
In 1994, BOULET et al. [15] suggested that a lack of
symptoms may be an insufficient tool for determining
whether asthma is in true remission. Indeed, there is
a weak correlation between symptoms on the one
hand and bronchial hyperresponsiveness and airways
inflammation on the other. Several investigators have
highlighted the possibility of diminished perception
of dyspnoea in subjects with more severe grades of
asthma, potentially leading to undertreatment in these
subjects [7–9]. Such an inverse relationship is not
a consistent finding [10]. In the present study there
was no correlation between dyspnoea perception and
PD20. The study population, however, had a limited
range of asthma severity.
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Fig. 1. –Borg scores at a 20% fall in the forced expiratory volume
in one second (FEV1) during methacholine (MCh) challenge in
subjects in clinical remission of atopic asthma and currently
asthmatic subjects. PS20: a perception score at a 20% fall in FEV1.
n=10. Horizontal bars represent mean values.
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Fig. 2. –Borg scores at a 20% fall in the forced expiratory volume
in one second (FEV1) during adenosine monophosphate (AMP)
challenge in subjects in clinical remission of atopic asthma and
currently asthmatic subjects. PS20: a perception score at a 20% fall
in FEV1. n=10. Horizontal bars represent mean values.
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Fig. 3. –Partial correlation coefficients between a provocative dose
causing a 20% fall in the forced expiratory volume in one second
(FEV1) (PD20) and a perception score at a 20% fall in FEV1
(PS20) with respect to methacholine (MCh) challenge in subjects
in clinical remission of atopic asthma and currently asthmatic
subjects. #: asthma; $: remission. r=0.23; p=0.34.
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Fig. 4. –Partial correlation coefficients between a provocative dose
causing a 20% fall in the forced expiratory volume in one second
(FEV1) (PD20) and a perception score at a 20% fall in FEV1
(PS20) with respect to adenosine monophosphate (AMP) challenge
in subjects in clinical remission of atopic asthma and currently
asthmatic subjects. #: asthma; $: remission. r=0.06; p=0.81.
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Reduced dyspnoea perception, during clinical
remission, could possibly explain the absence of
symptoms despite persistent airways inflammation
and bronchial hyperresponsiveness [4] found in these
subjects. Studies concerning symptom perception in
asymptomatic asthmatics are scarce. In the present
study subjects in clinical remission of atopic asthma
supposedly having no grade of asthma at all were
included. Given the ongoing airways inflammation
the authors recently documented in a considerable
proportion of these subjects [3, 4], it was very
important to show whether a diminished perception
of symptoms was present. The results of the present
study did not confirm that an unclear symptom
perception explains the lack of symptoms. Subjects
in clinical remission are obviously capable of detecting
airway narrowing at a similar level to currently
asthmatic subjects. Conversely, others found a poor
relationship between perception of spontaneous "daily
life" asthma and artificially-induced bronchoconstric-
tion [10, 11]. Therefore, the possibility that this is also
true for subjects in clinical remission of asthma cannot
be excluded. Thus, it might still be possible that as a
result of biomechanical, pathophysiological or psy-
chological factors, abnormal daily-life fluctuations in
airflow are not interpreted as asthma by subjects in
clinical remission [6, 16]. A fast decline in FEV1 as a
result of MCh- or AMP-induced bronchoconstriction
is probably less prone to interindividual differences,
and could thus explain the present findings. Never-
theless, since dyspnoea and other asthmatic symptoms
seem to be an interplay between the degree of
asthmatic inflammation and many other influences
including physical and psychological factors [6, 7], it
is suggested that the absence of asthmatic symptoms
in subjects regarded as ex-asthmatics should be inter-
preted with great care.
To conclude, the study indicates that the lack of
symptoms, despite persistent bronchial hyperrespon-
siveness and ongoing airways inflammation, during
clinical remission of asthma is not due to an unclear
symptom perception. Other factors, which include
physical and psychological ones, may play a role in
the apparent absence of symptoms in daily life. This is
a potential factor leading to undertreatment.
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